Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18346519.
- Also identified by DOI 10.1016/j.jpeds.2007.12.020 and PMC identifier 2390888.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.
Medical subject headings
- Adenine
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Bone Density
- HIV Infections
- Organophosphonates